Gilead Sciences PT Raised to $98.00 at Maxim Group (GILD)
Research analysts at Maxim Group raised their target price on shares of Gilead Sciences (NASDAQ:GILD) from $89.00 to $98.00 in a report released on Thursday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 30.49% from the company’s current price.
GILD has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday. They now have a $89.00 price target on the stock. Separately, analysts at Bank of America Corp. reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday. They now have a $74.45 price target on the stock, down previously from $107.00. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, December 23rd. Two research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $78.63.
Gilead Sciences (NASDAQ:GILD) opened at 75.10 on Thursday. Gilead Sciences has a 52-week low of $36.935 and a 52-week high of $76.11. The stock has a 50-day moving average of $72.61 and a 200-day moving average of $63.66. The company has a market cap of $115.2 billion and a price-to-earnings ratio of 41.32.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, October 29th. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.